Synapse - Vincent Miller

Results (270)

Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER climerization inhibitor, in non-small cell lung cancer (NSCLC) patients after prior chemotherapy

Meeting Abstract

Herbst, R.; Davies, A.; Johnson, B.; Natale, R.; Dang, T.; Murren, J.; Schiller, J.; Garland, L.; Miller, V.; Mendelson, D.; more...
Lung Cancer (2005)

Fulltext@MSK | Save

Measurements of total DNA and methylated tumor suppressor genes in the plasma of patients with metastatic non-small cell lung cancer (NSCLC) before, and after chemotherapy, as potential biomarkers for response to treatment

Meeting Abstract

Azzoli, C. G.; Park, S.; Gomez, J.; Krug, L.; Miller, V.; Rizvi, N.; Ben-Porat, L.; Danenberg, K.; Danenberg, P.; Kris, M.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Practical management of patients with non-small-cell lung cancer treated with gefitinib

Journal Article

Shah, N. T.; Kris, M. G.; Pao, W.; Tyson, L. B.; Pizzo, B. M.; Heinemann, M. H.; Ben-Porat, L.; Sachs, D. L.; Heelan, R. T.; Miller, V. A.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

Journal Article

Eberhard, D. A.; Johnson, B. E.; Amler, L. C.; Goddard, A. D.; Heldens, S. L.; Herbst, R. S.; Ince, W. L.; Jänne, P. A.; Januario, T.; Johnson, D. H.; more...
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Journal Article

Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E.
PLos Medicine (2005)

Fulltext@MSK | Save

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions